The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2021 | CRC highlights from ESMO WCGIC 2021
Juan Manuel O’Connor, MD, Institute Alexander Fleming, Buenos Aires, Argentina, shares his highlights from the ESMO World Congress on Gastrointestinal Cancer 2021, which included data from the Phase III open-label KEYNOTE-177 trial (NCT02563002), which assessed pembrolizumab in patients with microsatellite-instability–high advanced colorectal cancer. Additional highlights include results from the Phase III BEACON trial (NCT02928224), which investigated encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.
